Strikingly, STAMBPL1 silencing synergistically augmented the antitumor effect of PD‐1 blockade, since immunocompetent mice bearing STAMBPL1 KD‐Renca tumor exhibited suppressed tumor growth and improved overall survival rates upon αPD‐L1 therapy, compared to the mice bearing control‐Renca tumor following αPD‐L1 treatment (Figure 6L–N). This evidence concerns the gene STAMBPL1 and neoplasm.